We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Biogen Inc. (BIIB - Free Report) closed at $252.86, marking a -1.61% move from the previous day. This move lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 0.67%.
Coming into today, shares of the company had lost 3.8% in the past month. In that same time, the Medical sector lost 4.56%, while the S&P 500 lost 4.45%.
Wall Street will be looking for positivity from Biogen Inc. as it approaches its next earnings report date. In that report, analysts expect Biogen Inc. to post earnings of $3.97 per share. This would mark a year-over-year decline of 16.77%. Meanwhile, our latest consensus estimate is calling for revenue of $2.38 billion, down 5.01% from the prior-year quarter.
BIIB's full-year Zacks Consensus Estimates are calling for earnings of $15.25 per share and revenue of $9.69 billion. These results would represent year-over-year changes of -13.7% and -4.8%, respectively.
It is also important to note the recent changes to analyst estimates for Biogen Inc.These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.05% lower. Biogen Inc. is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Biogen Inc. has a Forward P/E ratio of 16.85 right now. This represents a no noticeable deviation compared to its industry's average Forward P/E of 16.85.
Meanwhile, BIIB's PEG ratio is currently 2.78. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Biogen Inc. (BIIB - Free Report) closed at $252.86, marking a -1.61% move from the previous day. This move lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 0.67%.
Coming into today, shares of the company had lost 3.8% in the past month. In that same time, the Medical sector lost 4.56%, while the S&P 500 lost 4.45%.
Wall Street will be looking for positivity from Biogen Inc. as it approaches its next earnings report date. In that report, analysts expect Biogen Inc. to post earnings of $3.97 per share. This would mark a year-over-year decline of 16.77%. Meanwhile, our latest consensus estimate is calling for revenue of $2.38 billion, down 5.01% from the prior-year quarter.
BIIB's full-year Zacks Consensus Estimates are calling for earnings of $15.25 per share and revenue of $9.69 billion. These results would represent year-over-year changes of -13.7% and -4.8%, respectively.
It is also important to note the recent changes to analyst estimates for Biogen Inc.These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.05% lower. Biogen Inc. is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Biogen Inc. has a Forward P/E ratio of 16.85 right now. This represents a no noticeable deviation compared to its industry's average Forward P/E of 16.85.
Meanwhile, BIIB's PEG ratio is currently 2.78. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.